
Supplementary Figure 1: Summary of clinical manifestations of patients with Majeed syndrome as described in literature. New features seen in the Indian cohort of patients are shown in **bold font**.



## Supplementary Table 1: Radiological features and treatment of our patient cohort with Majeed syndrome:

Patient number	1	2	3	4	5
Radiological findings:					
Skeletal survey	Subtle, smooth	Generalized reduced	Not done	Not done	Not done
	periosteal reaction	bone density, ankylosis			
	along the left	b/l elbows, osteophytes			
	proximal tibial	left elbow, flexion			
	metadiaphysis	deformity right elbow.			
		Subchondral sclerosis			
		along the proximal			
		articular surface of ulna			
Bone scan	Mild diffuse early	Normal	Increased uptake on	Increased uptake in	Increased blood
	and late-stage		early and late phase	proximal and distal	flow around right
	uptake in the entire		images around the	epiphysis left tibia	ankle and delayed
	left lower extremity		right wrist, knee and	with possible	increased uptake
	with more focal		ankle	extension in the	along the distal right
	uptake along the			shaft on both phases	femur and left tibia
	proximal tibia				
	corresponding to the				A follow up bone
	radiographic				scan with SPECT
	abnormality and				after seven years -
	mild areas of				increased early and
	increased uptake in				late phase uptake
	the tenth and				around the right
	eleventh vertebral				wrist and ankle
MRI	*Marrow and	Not done	Right proximal	MRI left lower	Moderate left
	periosteal edema		humeral, radial head,	extremity: small left	talonavicular
	along the left distal		distal radial	hip joint effusion,	effusion with mild

femoral	metaphyseal, carpal,	mild left femoral	to moderate edema
metadiaphysis and	left distal radial	neck edema and left	in the left talus,
bone marrow edema	metaphyseal, third	proximal medial	navicular, cuboid,
in the left talus and	metacarpal, right	tibial metaphyseal	cuneiform bones, 2 <sup>nd</sup>
navicular. Subtle	more than left distal	bone marrow	and 3 <sup>rd</sup> metatarsal
asymmetrical	femoral, left more	edema.	bases and the right
marrow edema at	than right proximal		5 <sup>th</sup> metatarsal shaft
proximal metaphysis	tibial bone marrow	Repeat b/l lower	
left tibia. Spine and	edema with subtle	extremity screening	
other bones were	periosteal edema and	MRI: Distal femoral	
normal. The long	fluid along the lower	metaphyseal bone	
bones showed	extremity and left	marrow edema with	
multiple transverse	third metacarpal	periostitis and	
metaphyseal lines	regions. The lesions	bilateral left more	
("zebra lines"),	were transphyseal	than right proximal	
likely due to	with extension of	tibial bone edema.	
pamidronate	bone marrow edema		
treatment	in the epiphyseal	#Resolution of the	
	regions in addition to	previous lesions in	
	metadiaphysis in	both lower limbs.	
	bilateral proximal	Mild bone marrow	
	tibia and mild to	edema in the left	
	moderate bilateral	distal	
	elbow joint effusions	metadiaphyseal	
		region of the radius	
		and adjacent	
		pronator quadratus	
		muscle in the distal	

				forearm with mild	
				edema in the medial	
				end of both clavicles	
Treatment:					
Treatment	Pamidronate,	Pamidronate, p.r.n	Oral prednisolone,	Pamidronate,	Oral prednisolone,
	methotrexate, p.r.n	diclofenac	methotrexate,	p. r. n naproxen	methotrexate,
	naproxen		azathioprine,		azathioprine,
			sulfasalazine,		sulfasalazine,
			Pamidronate		etanercept,
					adalimumab,
					pamidronate
			1	1	

<sup>\*=</sup> Two years into treatment; #= One year into treatment **Abbreviations:** b/l = Bilateral; y = years; m = months

Online supplement to: Majeed Syndrome: Five Cases With Novel Mutations From Unrelated Families in India With a Review of Literature. The Journal of Rheumatology. doi:10.3899/jrheum.201663

Supplementary Table 2: Novel *LPIN2* mutations identified in this cohort of patients and support for their pathogenicity based on *in silico* predictions and ACMG classification

Patient	Genomic	Codon	A D	Canacana	SIFT	M4-4	Dola-Dha	CADD	C-lina Al	ACMG
Patient	Genomic		gnomAD	Consequence	SIFI	Mutation	PolyPhen	CADD	SpliceAl	ACMG
	coordinates	change/	MAF			Taster				classification
		Amino acid								
		substitution								
1	Chr18:	c.2206C>T;	0.000003984	Missense	D	D	PD	32	-	VUS (PM1,
	2922166G>A	p.R736C								PM2, PP3)
2	Chr18:	c.2041delT;	0	Frameshift	-	-	-	-	-	Pathogenic
	2924439-	p.W681fs								(PVS1, PM2,
	2924441									PP3)
3	Chr18:	c.2174+4_	0	5' splice site	-	-	-	-	0.97	VUS (PM2,
	2923768_	2174+5del		intronic variant						PP3)
	2923769del			affecting 4						
				nucleotides						
				downstream						
				donor splice site						
				_						
				of exon 16						
4	Chr18:	c.1961G>A;	0	Missense	D	D	PD	29.9	-	VUS (PM1,
	2924522C>T	p.G654D								PM2, PP3)
5	Chr18:	c.1620+5G>C	0	5'splice site	-	D	-	22.5	0.7	VUS (PM2,
	2928584C>G			intronic variant						BP4)
				affecting 5						
				nucleotides						
				downstream of						
				donor splice site						
				of exon 11						
				OI CAUII I I						

NM014646.2, All five variants are conserved across all species.

ACMG classification criterion: Pathogenic moderate 1 (PM1) = Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation; Pathogenic moderate 2 (PM2) = Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or ExAC; Pathogenic supporting 3 (PP3) = Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc); Pathogenic Very strong (PVS1) = Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease; Benign supporting 4 (BP4) = Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)

**Abbreviations:** D=Deleterious; PD = Probable Damaging; VUS = Variant of uncertain significance; MAF = Minor allele frequency; ACMG = American College of Medical Genetics and Genomics

Supplementary Table 3: Salient features of twenty-five molecularly confirmed patients with Majeed syndrome reported in literature:

Authors/	Ancestry	Consanguinity	Gender/	Features	Pathogenic variant
number (n)			Age – onset /diagnosis		
Ferguson et al.	Arabic	+	F/9m/NA	Failure to thrive	Homozygous for
(3, 15-17)	Sibship 1			Recurrent fever	c.2201C>T;
n = 6				CRMO	p.Ser734Leu
				Microcytic anemia	
			M/NA/NA	<sup>a</sup> Skin lesions	
				Hepatosplenomegaly	
	Arabic	+	M/6m/NA	Failure to thrive	Homozygous for
	Sibship 2			Recurrent fever	c.2201C>T;
				CRMO	p.Ser734Leu
				Microcytic anemia	
			M/10m/NA	Sweet syndrome	
				Hepatosplenomegaly	
		+	* F/3w/NA	Failure to thrive	Homozygous for

	Arabic			<sup>b</sup> Recurrent fever	c.540_541del;
	Sibship 3			° CRMO	p.Cys181*
				<sup>d</sup> Microcytic anemia	
				* Splenomegaly	
				# Irritability	
			# M/2m/NA	# Delayed Puberty	
				#Pustulosis	
				#Contractures: UL/LL	
				#Maxillary bone	
				hyperplasia	
				#Prominent forehead	
				#Splenectomy	
Al – Mosawi et	Arabic	+	F/Neonatal/ UC	Recurrent fever	Homozygous for
al. (18)				CRMO	c.2327+1G>C;
n = 1				Microcytic anemia	p.Arg776Serfs*66
				Reticulocytosis	
				Mild neutropenia	
				Cholestatic jaundice	

				Hepatosplenomegaly	
Herlin et al.	Turkish	+	M/6m/29m	CRMO	Homozygous for
(14)	Sibship 4			Microcytic anemia	c.1312_1313del;
n = 2				Elevated IL-1β, IL-6, IL-8	p.Ser439Trpfs*15
				TNF-α	
			<sup>\$</sup> M/3m/13m	§ Recurrent fever	
Rao et al. (19)	Indian		M/2y/15y	Failure to thrive	Homozygous for
n = 2	Cousins			Delayed puberty	c.2241_2243delinsGG;
				CRMO	p.Tyr747*
				Microcytic anemia	
				Mild leucopenia	
				Hepatosplenomegaly	
			M/8y/13y	Failure to thrive	
				CRMO	
				Mild Microcytic anemia	
Fernandes et	NA	NA	M/6y/12y	CRMO	Homozygous for
al. (20)				Alpha – thalassemia minor	c.2327 + 1G>C;
n =1					p.Arg776Serfs*66

Moussa et al.	Arabic	+	<sup>@</sup> M/6m/5y	CRMO	Homozygous for
(21)	Sibship 5		F/4y/14y	Microcytic anemia (@mild)	c.2201C>T;
n =2			1/49/149		p.Ser734Leu
Al – Mosawi et	Arabic	+	<sup>⊥</sup> M/11m/UC	CRMO	Homozygous for
al. (22)	Sibship 6			Microcytic anemia	c.2327+1G>C;
n = 2			F/15m/UC	<sup>⊥</sup> Recurrent fever	p.Arg776Serfs*66
				<sup>⊥</sup> Neutropenia	
Karacan et al.	Turkish	NA	M/NA/9y	NA	Homozygous for
(23)					c.1456del;
n =1					p.Glu486Lysfs*20
Roy et al. (11)	Pakistani	+	F/Infancy/NA	Irritability	Homozygous for
n = 6	Family			Failure to thrive	c.2207 G>A;
				Recurrent fever	p.Arg736His
				°CRMO	
				Microcytic anemia	
			M/NA/NA (2 siblings)	CRMO	
			Mother/ NA/NA	Microcytic anemia	

			F (sib)/NA/NA	Mild anemia	
				Limb pain	
			Father/NA/NA	Non-specific knee pain	
Liu et al. (13)	Chinese	No	M/6m/UC	Recurrent fever	Compound heterozygous
n =1				Microcytic anemia	for
				Severe neutropenia	c.2327 + 1G > C;
					p.Arg776Serfs*66
					and
					c.1691_1694del;
					p.Arg564Lysfs*3
Bhuyan et al.	American		F/12m/4y	Dyserythropoietic anemia	Compound heterozygous
(9)				Bone pains	c.1550G>A;
n = 1					p.Arg517His and
					17.8kb deletion of exons
					7 to 18

In addition to these, twenty-five patients with pathogenic or likely pathogenic variants in *LPIN2*, six other patients (12) were reported to have a homozygous mutation in *LPIN2*, but these variants were not described.  $^a$ =Skin lesion resembling Sweet syndrome;  $^b$ = high grade; c= extensive involvement;  $^d$ = transfusion dependent;  $^e$ = nocturnal pain

**Abbreviations:** M=Male; F=Female;  $3^0$ =  $3^{rd}$  degree; NA= Not Available; w=weeks; m=months; y=years; CRMO =Chronic Recurrent Multifocal Osteomyelitis; UC = Unclear; UL = Upper Limb; LL = Lower Limb.